Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...
This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...
Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...
Four heads of iconic U.S. enterprises face turbulent, inherited challenges with elevated investor anxiety in 2025.
For those looking to attain a healthy body weight in 2025, there are a few options to consider. Dr. Will Cauthen, a board-certified surgeon at the Surgery Clinic of Tupelo who specializes in abdominal ...
In December 2024, the U.S. Equal Employment Opportunity Commission (“EEOC”) published a fact sheet addressing how federal ...
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback